3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Large-Cell, Anaplastic
2
Sexual Dysfunction, Physiological
1
Rare Tumor
1
Neuroblastoma
1
Lymphoma
1
Lung Diseases
1
Eunuchism
1
Erectile Dysfunction
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Nivolumab
28
pembrolizumab
24
cabozantinib
22
Ipilimumab
19
Specimen Handling
14
Magnetic Resonance Spectroscopy
13
Axitinib
12
lenvatinib
10
Radiosurgery
9
belzutifan
8
CTLA-4 Antigen
7
Biopsy
7
atezolizumab
6
cemiplimab
5
Radiotherapy
5
Bevacizumab
5
toripalimab
4
Everolimus
4
Blood Specimen Collection
4
avelumab
3
aldesleukin
3
X-Rays
3
Sunitinib
3
Standard of Care
3
Paclitaxel
3
zimberelimab
2
trastuzumab deruxtecan
2
tivozanib
2
spartalizumab
2
pazopanib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Renal Cell
×
alectinib
×
Clear all
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled